[HTML][HTML] Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology
MAC Bruin, GS Sonke, JH Beijnen… - Clinical …, 2022 - Springer
Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP)
inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer …
inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer …
[HTML][HTML] BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
Mutations in the tumor-suppressor genes BRCA1 and BRCA2 resulting in BRCA1/2
deficiency are frequently identified in breast, ovarian, prostate, pancreatic, and other …
deficiency are frequently identified in breast, ovarian, prostate, pancreatic, and other …
Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data
M Friedlander, YC Lee, WP Tew - American Society of Clinical …, 2023 - ascopubs.org
The use of poly (ADP-ribose) polymerase (PARP) inhibitor therapy is standard care in the
management of patients with various malignancies including ovarian, breast, prostate, and …
management of patients with various malignancies including ovarian, breast, prostate, and …
Medicinal chemistry perspective on targeting mono-ADP-ribosylating PARPs with small molecules
MG Nizi, MM Maksimainen, L Lehtio… - Journal of Medicinal …, 2022 - ACS Publications
Major advances have recently defined functions for human mono-ADP-ribosylating PARP
enzymes (mono-ARTs), also opening up potential applications for targeting them to treat …
enzymes (mono-ARTs), also opening up potential applications for targeting them to treat …
[HTML][HTML] Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
X Tian, L Chen, D Gai, S He, X Jiang… - Frontiers in …, 2022 - frontiersin.org
Background: Several poly ADP ribose polymerase inhibitors (PARPis) are currently
approved for the treatment of a variety of cancers. The safety profile of PARPis has not yet …
approved for the treatment of a variety of cancers. The safety profile of PARPis has not yet …
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation
LE Butel-Simoes, TJ Haw, T Williams, S Sritharan… - …, 2023 - Am Heart Assoc
Cardiovascular disease and cancer are 2 of the leading causes of death worldwide.
Although improvements in outcomes have been noted for both disease entities, the success …
Although improvements in outcomes have been noted for both disease entities, the success …
[HTML][HTML] Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches
Simple Summary Poly (ADP-ribose) polymerase (PARP) inhibitors treat breast and ovarian
cancers. PARP-inhibition (PARPi), which affects cell survival by re-regulating DNA repair …
cancers. PARP-inhibition (PARPi), which affects cell survival by re-regulating DNA repair …
[HTML][HTML] Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer
PARP inhibitors (PARPi) have revolutionized the therapeutic landscape of epithelial ovarian
cancer (EOC) treatment with outstanding benefits in regard to progression-free survival …
cancer (EOC) treatment with outstanding benefits in regard to progression-free survival …
Management of hypertension in patients with cancer: challenges and considerations
S Pandey, A Kalaria, KD Jhaveri… - Clinical Kidney …, 2023 - academic.oup.com
The survival rates of many cancers have significantly improved due to recent advancements
in cancer screening and therapeutics. Although better cancer outcomes are encouraging …
in cancer screening and therapeutics. Although better cancer outcomes are encouraging …
[HTML][HTML] Everything comes with a price: the toxicity profile of DNA-damage response targeting agents
F Martorana, LA Da Silva, C Sessa, I Colombo - Cancers, 2022 - mdpi.com
Simple Summary DNA damage induces genome instability, which may elicit cancer
development. Defects in the DNA repair machinery further enhance cancer predisposition …
development. Defects in the DNA repair machinery further enhance cancer predisposition …